Outcomes According to KRAS/TP53 Mutational Status in Patients With Non-Squamous PD-L1–High NSCLC After First-Line Pembrolizumab
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Thoracic Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Outcome of first-line treatment with pembrolizumab according to KRAS/TP53 mutational status for non-squamous PD-L1 high (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer (nNGM)
J Thorac Oncol 2023 Dec 12;[EPub Ahead of Print], P Bischoff, M Reck, T Overbeck, P Christopoulos, A Rittmeyer, H Lüders, J Kollmeier, J Kulhavy, M Kemper, N Reinmuth, J Röper, M Janning, L Sommer, L Aguinarte, M Koch, M Wiesweg, C Wesseler, CF Waller, D Kauffmann-Guerrero, A Stenzinger, S Stephan-Falkenau, M Trautmann, S Lassmann, M Tiemann, F Klauschen, M Sebastian, F Griesinger, J Wolf, S Loges, N FrostFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.